Vertex signs agreement to acquire Crinetics for $10bn
Approved unanimously by both companies’ boards, the acquisition will see Vertex pay $85.00 per share in cash for all outstanding shares of Crinetics. It is expected to close
Evogene and Tel Aviv University’s Blavatnik Center for Drug Discovery (BCDD) have announced a collaboration that aims to expedite the development of small-molecule drug discovery originating from Israeli academic research.